Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Multi-Center,Study Evaluating the Effects of Eplerenone Versus Placebo on Ventricular Remodeling in Patient's With Left Ventricular Systolic Dysfunction (EF less than 35 percent) and Mild to Moderate Heart Failure

Next Previous
Trial Profile

A Randomized, Double-Blind, Multi-Center,Study Evaluating the Effects of Eplerenone Versus Placebo on Ventricular Remodeling in Patient's With Left Ventricular Systolic Dysfunction (EF less than 35 percent) and Mild to Moderate Heart Failure

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eplerenone (Primary)
  • Indications Heart failure; Left ventricular dysfunction
  • Focus Pharmacodynamics
  • Acronyms REMODEL
  • Sponsors Pfizer

Most Recent Events

  • 05 May 2026 Primary endpoint has been met. (Difference between eplerenone and placebo in change from baseline in LV end diastolic volume index (EDVi) determined by equilibrium-gated radionuclide ventriculography (RVG))
  • 05 May 2026 According to Regeneron Pharmaceuticals, Inc media release,data from this trial were shared today in a late-breaking oral presentation at the 2026 Digestive Disease Week (DDW) conference.
  • 05 May 2026 Results presented at Regeneron Pharmaceuticals, Inc media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top